Extended-spectrum and Metallo-beta lactamase enzymes mediated resistance in Pseudomonas aeruginosa in clinically isolated specimens
DOI:
https://doi.org/10.48129/kjs.v48i2.8495Keywords:
words, Antimicrobial resistance, DDST, ESBL, imipenem-EDTA test, MBL, P. aeruginosaAbstract
Pseudomonas aeruginosa is one of the leading opportunistic pathogens, frequently highlighted for the production of ESBL and MBL enzymes. This is believed to be the primary inhabitant of soil due to its adaptive nature and can survive in aquatic and even in toxic environment. The current study was aimed to screen ESBL and MBL producing and MDR strains of P. aeruginosa. Clinical specimens collected from patients and were screened for the presence of P. aeruginosa. After identification, all the isolates were tested for the sensitivity pattern following Kirby-Bauer disc diffusion method. The presence of ESBL and MBL enzymes were detected following DDST and IMP-EDTA detection tests respectively. Totally 1369 clinical specimens were collected, among which 126 (9.20%) specimens grown the colonies of P. aeruginosa on culture media. 54.76% (69/126) of the positive specimens confirmed in female population, whereas, 45.24% (57/126) in male population. High frequency rate, (n=43/126) was detected in age group ≥31 year, followed by 21-30 (n=35/126), and 11-20 (n=34/126) age group, the minimal frequency (n=14/126) was detected in age group 0-14. The sensitivity pattern showed that majority of the isolates were resistant, but class carbapenem, aminoglycosides and some other antibiotics i.e. sulbactam-Cefoperazone, tazobactam-piperacillin, tigecycline and Fosfomycin showed best results to P. aeruginosa. it is concluded that the emergence of resistance due to ESBL and MBL enzymes in P. aeruginosa is directly linked with public health concern because these strains are almost resistant to a wide range of antibiotics and only limited antibiotics are potent against these organisms.
References
Ahmad, M., Hassan, M., Khalid, A., Tariq, I., Asad, M. H. H. B., Samad, A., Mahmood, Q. & Murtaza, G. (2016) Prevalence of extended spectrum β-lactamase and antimicrobial susceptibility pattern of clinical isolates of Pseudomonas from patients of Khyber Pakhtunkhwa, Pakistan. BioMed research international, 2016.
Al-Agamy, M. H., Shibl, A. M., Tawfik, A. F., Elkhizzi, N. A. & Livermore, D. M. (2012) Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia. Journal of Chemotherapy, 24: 97-100.
Bush, K. (2010) Bench-to-bedside review: the role of β-lactamases in antibiotic-resistant Gram-negative infections. Critical Care, 14: 224.
Bush, K. & Jacoby, G. A. (2010) Updated functional classification of β-lactamases. Antimicrobial agents and chemotherapy, 54: 969-976.
Cavallo, J., Hocquet, D., Plesiat, P., Fabre, R. & Roussel-Delvallez, M. (2007) Susceptibility of Pseudomonas aeruginosa to antimicrobials: a 2004 French multicentre hospital study. Journal of Antimicrobial Chemotherapy, 59: 1021-1024.
Cheesbrough, M. (2006) District laboratory practice in tropical countries, Cambridge university press.
Cockerill, F. R. (2011) Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement, Clinical and Laboratory Standards Institute (CLSI).
Cowan, S. T. & Steel, K. J. (2004) Cowan and Steel's manual for the identification of medical bacteria, Cambridge university press.
Freitas, A. L. P. D. & Barth, A. L. (2002) Antibiotic resistance and molecular typing of Pseudomonas aeruginosa: focus on imipenem. Brazilian Journal of Infectious Diseases, 6: 01-06.
Gupta, R., Malik, A., Rizvi, M. & Ahmed, S. M. (2016) Incidence of multidrug-resistant Pseudomonas spp. in ICU patients with special reference to ESBL, AMPC, MBL and biofilm production. Journal of global infectious diseases, 8: 25.
Hawser, S., Bouchillon, S., Lascols, C., Hackel, M., Hoban, D., Badal, R. & Canton, R. (2012) Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008–2009). Clinical Microbiology and Infection, 18: 253-259.
Javiya, V. A., Ghatak, S. B., Patel, K. R. & Patel, J. A. (2008) Antibiotic susceptibility patterns of Pseudomonas aeruginosa at a tertiary care hospital in Gujarat, India. Indian journal of pharmacology, 40: 230.
Livermore, D. M. (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical infectious diseases, 34: 634-640.
Noyal, M., Menezes, G., Harish, B., Sujatha, S. & Parija, S. (2009) Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria. Indian Journal of Medical Research, 129.
Nseir, S., Di Pompeo, C., Brisson, H., Dewavrin, F., Tissier, S., Diarra, M., Boulo, M. & Durocher, A. (2006) Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Critical Care, 10: R143.
Pandya, N. P., Prajapati, S. B., Mehta, S. J., Kikani, K. M. & Joshi, P. J. (2011) Evaluation of various methods for detection of metallo-β-lactamase (MBL) production in gram negative bacilli. Int J Biol Med Res, 2: 775-7.
Peshattiwar, P. D. & Peerapur, B. V. (2011) ESBL and MBL mediated resistance in Pseudomonas aeruginosa: An emerging threat to clinical therapeutics. J Clin Diagn Res, 5: 1552-4.
Rafiee, R., Eftekhar, F., Tabatabaei, S. A. & Tehrani, D. M. (2014) Prevalence of extended-spectrum and metallo β-lactamase production in AmpC β-lactamase producing Pseudomonas aeruginosa isolates from burns. Jundishapur journal of microbiology, 7.
Simoens, S., De Corte, N. & Laekeman, G. (2006) Clinical practice and costs of treating catheter-related infections with teicoplanin or vancomycin. Pharmacy practice, 4: 68.
Thokar, M. A., Fomda, B. A., Maroof, P., Ahmed, K., Bashir, D. & Bashir, G. (2010) Proliferation of extended spectrum ß–lactamase (ESBL) producing Gram negative bacteria, diagnostic inputs and impact on selection of Antimicrobial therapy. Phys Acad, 4: 25-31.
Tiersma, Y. (2013) β-Lactamase-producing bacteria How can I resist you? M. Sc. dissertation submitted to department of Biology Science Utrecht University.
Yazdi, M., Nazemi, A., Mirinargasi, M., Jafarpour, M., Sharifi, S. & Branch, T. (2012) Genotypic versus phenotypic methods to detect extended-spectrum beta-lactamases (ESBLs) in uropathogenic Escherichia coli. Ann Biol Res, 3: 2454-8.
Yong, D., Lee, K., Yum, J. H., Shin, H. B., Rossolini, G. M. & Chong, Y. (2002) Imipenem-EDTA disk method for differentiation of metallo-β-lactamase-producing clinical isolates of Pseudomonas spp. and Acinetobacter spp. Journal of clinical microbiology, 40: 3798-3801.
Zafer, M. M., Al-Agamy, M. H., El-Mahallawy, H. A., Amin, M. A. & Ashour, M. S. E.-D. (2014) Antimicrobial resistance pattern and their beta-lactamase encoding genes among Pseudomonas aeruginosa strains isolated from cancer patients. BioMed research international, 2014.
